It started with an ambitious and, at the time, an unheard-of plan in 1993: to make cancer clinical trials accessible to the community without the support of an academic institution. Our dedicated team established the first Phase 1 program in the community setting in 1997, which has grown to become one of the largest programs of its kind in the world. Formally established as Sarah Cannon Research Institute in 2004, it brings together community-based physicians, researchers and clinicians that have conducted more than 600+ first-in-human trials and has been a clinical trial leader in the majority of approved cancer therapies in the last decade.

Now, our reach far extends beyond clinical trials for cancer. In 2012, Sarah Cannon became the Cancer Institute of HCA Healthcare, to offer cutting-edge clinical research along with integrated cancer services from diagnosis through recovery. Today, Sarah Cannon provides patients with convenient access to world-class cancer care with more than 70 accredited centers across the US and UK. Sarah Cannon’s cancer programs include individualized patient navigation provided by oncology-trained nurses, ~ 1,200 blood and marrow transplants performed annually throughout the Sarah Cannon Transplant and Cellular Therapy Network, and molecular profiling capabilities to personalize treatment plans. Through its services, Sarah Cannon is providing state-of-the-art cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center.

Additionally, Sarah Cannon has a full-service contract research organization (CRO), Sarah Cannon Development Innovations, and an international drug development program. Thanks to the vision and dedication of Sarah Cannon Research Institute’s pioneering researchers, a wide variety of innovative cancer treatment options are available to patients in their local communities through community-based clinical trials and a full continuum of coordinated care through Sarah Cannon. To learn more, see our timeline below.